Literature DB >> 27660568

Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic.

Kelly Shum1, Amber Solivan2, Parham Parto3, Nichole Polin1, Eiman Jahangir1.   

Abstract

BACKGROUND: Because of the improvements in survival rates, patients with breast cancer are now more likely to die from cardiovascular disease than from cancer. Thus, providing appropriate preventive cardiovascular care to patients with cancer is of the utmost importance.
METHODS: We retrospectively compared the cardiovascular risk and management of 146 women treated at the Cardio-Oncology (Cardio-Onc) and the Obstetrics and Gynecology (Ob-Gyn) clinics. We calculated cardiovascular risk using the American College of Cardiology (ACC)/American Heart Association (AHA) atherosclerotic cardiovascular disease (ASCVD) risk calculator and the Framingham Risk Score Calculator. We also determined the prevalence of appropriate statin use according to both the 2013 ACC/AHA and the 2002 Adult Treatment Panel (ATP) III lipid guidelines.
RESULTS: The 10-year ASCVD risk score was not significantly different between the 2 cohorts. More patients in the Ob-Gyn cohort with an ASCVD risk score >7.5% were already appropriately on statins compared to patients in the Cardio-Onc cohort (60.9% vs 31.0%, respectively, P=0.003), but after the first Cardio-Onc visit, 4 additional patients with breast cancer were prescribed statins (44.8% total). Fourteen (19.2%) Cardio-Onc patients had a high Framingham Risk Score compared to 6 (8.2%) Ob-Gyn patients.
CONCLUSION: We demonstrated that the ASCVD risk is similar between women with breast cancer attending the Cardio-Onc clinic and the women without breast cancer attending the Ob-Gyn clinic, but the Cardio-Onc cohort had significantly more patients with a high Framingham Risk Score. Both clinics had similarly poor rates of appropriate statin prescribing rates according to the ATP III guidelines.

Entities:  

Keywords:  Atherosclerosis; breast neoplasms; cardiotoxicity; cardiovascular diseases; hydroxymethylglutaryl-CoA reductase  inhibitors; risk assessment

Year:  2016        PMID: 27660568      PMCID: PMC5024801     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  29 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

Authors:  Michael S Ewer; Scott M Lippman
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

Review 3.  Cholesterol and breast cancer pathophysiology.

Authors:  Erik R Nelson; Ching-yi Chang; Donald P McDonnell
Journal:  Trends Endocrinol Metab       Date:  2014-11-04       Impact factor: 12.015

4.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

Authors:  G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

5.  Simvastatin exhibits antiproliferative effects on spheres derived from canine mammary carcinoma cells.

Authors:  Cristian G Torres; Araceli Olivares; Caroll Stoore
Journal:  Oncol Rep       Date:  2015-03-13       Impact factor: 3.906

6.  27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.

Authors:  Erik R Nelson; Suzanne E Wardell; Jeff S Jasper; Sunghee Park; Sunil Suchindran; Matthew K Howe; Nicole J Carver; Ruchita V Pillai; Patrick M Sullivan; Varun Sondhi; Michihisa Umetani; Joseph Geradts; Donald P McDonnell
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

7.  Radiation-induced cardiovascular disease.

Authors:  Negareh Mousavi; Anju Nohria
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

8.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

Authors:  L J Steinherz; P G Steinherz; C T Tan; G Heller; M L Murphy
Journal:  JAMA       Date:  1991-09-25       Impact factor: 56.272

9.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

Review 10.  Radiation-induced heart disease: pathologic abnormalities and putative mechanisms.

Authors:  Neil K Taunk; Bruce G Haffty; John B Kostis; Sharad Goyal
Journal:  Front Oncol       Date:  2015-02-18       Impact factor: 6.244

View more
  4 in total

1.  Prognostic importance of coincidental coronary artery calcification on FDG-PET/CT oncology studies.

Authors:  Huda El Mais; Robert Kay; Hassan Almubarak; Jennifer M Rowe; Alyssa L S Chow; Terrence Ruddy; Rob S Beanlands; Andrew M Crean; Benjamin J W Chow; Eugene C Y Leung; Gary R Small
Journal:  Int J Cardiovasc Imaging       Date:  2020-11-25       Impact factor: 2.357

2.  Changes in cardiovascular disease risk and risk factors among women with and without breast cancer.

Authors:  Chelsea Anderson; Hazel B Nichols; Allison M Deal; Yong-Moon Mark Park; Dale P Sandler
Journal:  Cancer       Date:  2018-10-06       Impact factor: 6.860

3.  miR-488-3p Protects Cardiomyocytes against Doxorubicin-Induced Cardiotoxicity by Inhibiting CyclinG1.

Authors:  Mingjing Yan; Yuan Cao; Que Wang; Kun Xu; Lin Dou; Xiuqing Huang; Beidong Chen; Weiqing Tang; Ming Lan; Bing Liu; Kaiyi Zhu; Yao Yang; Shenghui Sun; Xiyue Zhang; Yong Man; Mingyan Hei; Tao Shen; Jian Li
Journal:  Oxid Med Cell Longev       Date:  2022-02-10       Impact factor: 6.543

4.  Reporting of coronary artery calcification on chest CT studies in breast cancer patients at high risk of cancer therapy related cardiac events.

Authors:  William J Phillips; Christopher Johnson; Angeline Law; Michele Turek; Alex R Small; Joao R Inacio; Susan Dent; Terrence Ruddy; Rob S Beanlands; Benjamin J W Chow; Gary R Small
Journal:  Int J Cardiol Heart Vasc       Date:  2018-02-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.